CRE26-060: Triple Threat: Co-occurrence of Hypogammaglobulinemia, SMARCA4-Deficient Lung Cancer, and Stage IV Mantle Cell Lymphoma With Sustained Immunotherapy Response
20260 citationsJournal Article
Field-Weighted Citation Impact: 0.00
CRE26-060: Triple Threat: Co-occurrence of Hypogammaglobulinemia, SMARCA4-Deficient Lung Cancer, and Stage IV Mantle Cell Lymphoma With Sustained Immunotherapy Response | Researchclopedia